It has been more than five months since an Italian court in Milan awarded compensation to the family of a young boy who developed autism from a six-in-one hexavalent vaccine manufactured by corrupt British drug giant GlaxoSmithKline (GSK), and the U.S. media is still nowhere to be found in reporting on this breakthrough ruling.
On September 24, 2014, Italy’s version of the National Vaccine Injury Compensation Program agreed that GSK’s “INFANRIX Hexa” vaccine for polio, diphtheria, tetanus, hepatitis B, pertussis and haemophilus influenza type B induced permanent autism and brain damage in the previously healthy child, whose name has been kept private for safety.
The vaccine, which contains multiple antigens, thimerosal (mercury), multiple forms of aluminum, formaldehyde, recombinant (genetically modified) viral components and various chemical preservatives,[PDF] demonstrably caused the young boy to regress into autism shortly after he received all three doses of the vaccine, prompting his family to petition the case before Italy’s Ministry of Health.
When the Ministry rejected it, the family proceeded to file a lawsuit, which is no longer an option in the U.S. thanks to a Supreme Court ruling that exempts drug companies from legal liability when their products harm, permanently disfigure or kill people.
After listening to expert medical testimony, the Italian court remarkably concluded that the boy suffered permanent harm as a result of the vaccine, and particularly its neurotoxic mercury and aluminum components. …